ClinicalTrials.gg
Not yet recruitingNCT06951971Updated Apr 30, 2025

Dose-modified Emapalumab and Ruxolitinib (E-Ru) Regimens for Hemophagocytic Lymphohistiocytosis

A Phase 2/3 interventional study of dose-modified E-Ru and Salvage treatment and follow-up in Hemophagocytic Lymphohistiocytosis (HLH), sponsored by The First Affiliated Hospital of Soochow University. Not yet recruiting at 1 site in China. Open to participants aged 1 Year to 70 Years. Per ClinicalTrials.gov, last updated 2025-04-30.

Sponsored by The First Affiliated Hospital of Soochow University · Phase 2/3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
1 Year to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 40 studies in Lymphohistiocytosis, Hemophagocytic with a site in China — 15 open to participants now, 15 under way, 3 of them phase 3. Lymphohistiocytosis, Hemophagocytic · China.

Planned enrollment
18th of 32
30 · median 39
Started
2025
with 3 others
Phase 2/3
3 of 40
2 open now
Primary completion
2027-06
later than 12 of 14 live
Registered
33rd of 40
by date
Lead sponsor
2 of 40
The First Affiliated Hospital of Soochow University

Among the 40 studies in Lymphohistiocytosis, Hemophagocytic with a site in China, this one is the 18th largest by planned enrollment of the 32 interventional ones that give a count, is one of 4 that started in 2025, is one of 3 in phase 2/3, reaches primary completion later than 12 of the 14 other live ones, and was the 33rd registered.

Lymphohistiocytosis, Hemophagocytic

111 studies on the registry are indexed under Lymphohistiocytosis, Hemophagocytic; 41 are open to participants now.

Browse Lymphohistiocytosis, Hemophagocytic studies →

Open to participants now

15 of the 40 studies in Lymphohistiocytosis, Hemophagocytic with a site in China are open now. Recruiting first, the newest first:

9 more — sign in →

All 15 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 26 Lymphohistiocytosis, Hemophagocytic studies recruiting now, 14 (54%) set no upper age limit and 8 (31%) stop at 75 or younger; 15 take children under 18; 2 take healthy volunteers.

This study: 1 Year to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 40 studies in Lymphohistiocytosis, Hemophagocytic with a site in China, or all of them as a file.
02

Study summary

This study is trying to evaluate the efficacy and safety of dose-modified Emapalumab and Ruxolitinib (E-Ru) regimens for the treatment of active hemophagocytic lymphohistiocytosis.

Read the detailed description

This clinical trial is designed to evaluate a new treatment strategy for patients with active Hemophagocytic Lymphohistiocytosis (HLH)-a rare but severe immune disorder characterized by excessive inflammation and immune system activation. HLH can be life-threatening if not treated effectively.

The study is prospective and multicenter, meaning it will be conducted at multiple hospitals and medical institutions, and patients will be followed over time to assess treatment outcomes.

We aim to test the combination of two medications:

  1. Emapalumab, a monoclonal antibody that blocks interferon-gamma, a key driver of the overactive immune response seen in HLH. In this trial, it will be used at a lower-than-standard dose to reduce potential side effects.
  2. Ruxolitinib, a JAK1/2 inhibitor that can reduce inflammation by interfering with immune signaling pathways. It will be administered at a higher-than-standard dose to enhance its therapeutic effects.
03

Conditions studied

  • Hemophagocytic Lymphohistiocytosis (HLH)
04

Who can participate

Ages eligible
1 Year to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Fulfillment of at least five of the eight HLH-2004 criteria for HLH;
  2. Age 1-70 years old;
  3. No prior chemotherapy for HLH;
  4. Confirmed not pregnant and willing to use effective measures during the study period, with the last dose of medication administered at least 12 months prior;
  5. Signed prior to study participation.

Exclusion criteria

Exclusion Criteria:

  1. According to the (NYHA) score, patients with heart disease of grade II or above (including grade II);
  2. -infected patients;
  3. Patients with severe renal dysfunction ( \<15 mL/min);
  4. Patients with severe liver cirrhosis (MELD score>20);
  5. Uncontrollable infections (including lung infections, intestinal infections, etc.);
  6. Have serious mental illness;
  7. Have a history of active tumor;
  8. Participate in other clinical investigators at the same time;
  9. People with central nervous system involvement;
  10. Exclusion criteria related to concomitant medication.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    E-Ru for HLH

    dose-modified Emapalumab+Ruxolitinib for the treatment of HLH patients.

    Drug: dose-modified E-Ru · Other: Salvage treatment and follow-up

Interventions

  • Drugdose-modified E-Ru

    Emapalumab (1-2 mg/kg intravenously once weekly for 8 weeks) + Ruxolitinib (15-30 mg orally twice daily for 8 weeks)

  • OtherSalvage treatment and follow-up

    1) for patients who did not respond to the E-Ru regimen after 7 days or who relapsed at any point during treatment, a rescue regimen such as HLH-94 or doxorubicin-etoposide-methylprednisolone (DEP) was administered; 2) for patients diagnosed with lymphoma after enrollment, chemotherapy was initiated; 3) for patients who completed 8 weeks of treatment without recurrence and had no detected HLH-related gene mutations, follow-up was initiated; and 4) for patients who met the criteria for allo-HSCT, allo-HSCT was performed.

06

What researchers measure

Primary outcomes

  1. 60-days OS

    overall survival (OS) rate at 60 days (2-month OS)

    Time frame: 60 days

Secondary outcomes

  1. Response rate

    The ORR was defined as the percentage of patients with a complete response (CR), a partial response (PR), or an improvement in the measures of HLH.

    Time frame: 7, 14, 28, and 56 days

  2. Security

    Adverse events (AEs) were assessed according to the National Cancer Institute Common Terminology Criteria for Adverse Events, version 5.0 (CTCAE 5.0).

    Time frame: 7, 14, 28, and 56 days

  3. EFS

    event-free survival, defined as the time from the first administration of E-Ru until no response on day 7, disease progression or death from any cause

    Time frame: 6 months

  4. Overall survival

    OS (defined as the time from the first administration of E-Ru until death from any cause)

    Time frame: 6 months

  5. Trend of related indicators

    Changes in biomarkers between baseline and post-treatment.

    Time frame: 7, 14, 28, and 56 days

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jun 2025; primary completion for Jun 2027, 24 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 23, 2025
First posted
Apr 30, 2025
StartEst.
Jun 1, 2025
Primary completionEst.
Jun 1, 2027
CompletionEst.
Jun 1, 2028
Last update
Apr 30, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 30, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06951971
Responsible party
Xuefeng He (The First Affiliated Hospital of Soochow University, The First Affiliated Hospital of Soochow University) — Principal investigator
First posted
Apr 30, 2025
Start date
Jun 1, 2025 (estimated)
Primary completion
Jun 1, 2027 (estimated)
Completion
Jun 1, 2028 (estimated)
Last update
Apr 30, 2025

Study contacts

Yue Song, Dr
Contact
xueqifeng1992@163.com
+86 18810253070
Xuefeng He, Dr.
principal investigator · The First Affiliated Hospital of Soochow University

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion